Predict your next investment

Venture Capital

See what CB Insights has to offer

Investments

7

Portfolio Exits

4

About Tako Ventures

Tako Ventures is the venture arm of Larry Ellison, founder and CEO of Oracle Corporation.

Tako Ventures Headquarter Location

San Francisco, California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Tako Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Tako Ventures in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Tako Ventures News

ACROMEC’s associated Life Science Incubator launches Co-working Labspace

Sep 24, 2021

SINGAPORE, Sep 24, 2021 – (ACN Newswire) – ACROMEC Limited (ACROMEC; SGX: 43F), a specialist engineering services provider, announced that subsidiary ACROMEC Engineers Pte Ltd (ACROMEC Engineers) through joint-venture associate Life Science Incubator Pte Ltd, has launched the first Life Science Incubator co-working laboratory space, with a ceremony on location at the German Centre, International Business Plaza, Singapore. The ceremony was attended by Mr Alvin Tan, Minister of State, Ministry of Culture, Community and Youth and Ministry of Trade & Industry and others from the Economic Development Board, Enterprise Singapore, SGInnovate, A*STAR, NTUitiv and NUS accelerator. Members of Life Science Incubator’s current network of some 20 industry partners, including Merck, also attended the event. Serving early-stage bio and pharma start-ups, companies and entrepreneurs in the MedTech, Biotech, Biopharma and FoodTech sectors, Life Science Incubator will provide flexible co-working laboratory spaces for research and development. With access to communal state-of-the-art technologies and facilities, start-ups will be able to fully focus on innovation and talent in science without having to think about hefty infrastructure capital. Said Niamh Madden, General Manager of Life Science Incubator, “Today marks the start of our exciting journey at the Life Science Incubator. We look forward to supporting science and technology start-ups and being an integral launchpad for their endeavours. With our strong network of partner companies, we are confident that the incubator will become a vibrant centre of entrepreneurship, technology and science.” Said Mr Lim Say Chin, Executive Chairman and Managing Director of ACROMEC, “The successful completion and launch of the Life Science Incubator attests to ACROMEC’s track record and success as a specialist engineering provider for controlled environments. We are excited to be a part of this vibrant ecosystem and will continue to serve companies and start-ups in the life science, biotech, healthcare, and research sectors.” In July, the Group announced that wholly-owned subsidiary ACROMEC Engineers had entered into a joint-venture agreement with strategic partner Tako Ventures to build, own, and operate JVCo and co-working laboratory facilities. JVCo is 30% owned by the Group through ACROMEC Engineers, while Tako Ventures holds the remaining 70% stake, managing JVCo and the Life Science Incubator. ACROMEC Engineers undertook the design, construction, and fitting-out works for the 600 square meter Life Science Incubator’s co-working lab facilities, which includes 8 suites, 51 lab benches, and 1 operating theatre. About ACROMEC Limited SGX Catalyst-listed ACROMEC (SGX: 43F) is an established specialist engineering services provider with more than 20 years of acquiring expertise in the design and construction of facilities requiring controlled environments, such as laboratories, medical and sterile facilities and cleanrooms. Amongst its customers, ACROMEC counts hospitals & medical centres, government agencies, educational institutions, research & development companies and multinational units, pharmaceutical, semiconductor manufacturing and engineering companies. For more information, visit www.acromec.com . ACROMEC share information through SGX (43F), Bloomberg (ACRO.SG) and ThomsonReuters (ACRO.SI). Analyst & Media contact:

Tako Ventures Investments

7 Investments

Tako Ventures has made 7 investments. Their latest investment was in Theranos as part of their Series C - II on July 7, 2010.

CBI Logo

Tako Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/16/2010

Series C - II

Theranos

$45M

No

12/8/2006

Series C

Subscribe to see more

$99M

Subscribe to see more

10

6/13/2005

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

10/16/2004

Series B

Subscribe to see more

$99M

Subscribe to see more

10

11/9/1999

Unattributed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/16/2010

12/8/2006

6/13/2005

10/16/2004

11/9/1999

Round

Series C - II

Series C

Unattributed VC

Series B

Unattributed VC - II

Company

Theranos

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$45M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

10

10

10

10

Tako Ventures Portfolio Exits

4 Portfolio Exits

Tako Ventures has 4 portfolio exits. Their latest portfolio exit was Pillar Data Systems on June 29, 2011.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/29/2011

Acquired

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

6/29/2011

00/00/0000

00/00/0000

00/00/0000

Exit

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.